The multichain interleukin-2 receptor: a target for immunotherapy.
about
DAB486IL-2 fusion toxin in refractory rheumatoid arthritis.Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the alpha subunit of the receptor.Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts.Postpericardiotomy syndrome in pediatric heart transplant recipients. Immunologic characteristics.131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission.Impact of antigenemia on the bioactivity of infused anti-Tac antibody: implications for dose selection in antibody immunotherapiesInterleukin-2 receptor and ovarian cancer.Combined use of an immunotoxin and cyclosporine to prevent both activated and quiescent peripheral blood T cells from producing type 1 human immunodeficiency virus.Cytotoxic agents directed to peptide hormone receptors: defining the requirements for a successful drug.Metabolism of Tac (IL2Ralpha): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding.Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.Novel antibodies as anticancer agents.Anti-GM-CSF monoclonal antibody therapy for refractory acute leukemia.Cancer therapy with radiolabeled antibodies. An overview.Detection of homing, proliferation, and infiltration sites of adult T cell leukemia cells in severe combined immunodeficiency mice using radiometric techniques.The biological therapy of acute and chronic leukemia.Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments.Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions.
P2860
Q33492932-A00BF2DF-78A1-4B28-8455-E6EB4BCC7364Q33560410-F385FAEE-937B-473B-9035-BC88D132DAE1Q34416149-2026480D-427F-4D15-9D26-D4AE337B61C0Q34762427-902BF049-D010-4CB4-8697-7297722ABCD1Q35655689-AEE371FB-F1FF-4937-A6BB-70E1FAE7B615Q35849468-B25DE148-025B-4BE6-A784-407F52E6A40BQ35888457-A55A5BA6-6B69-4A1C-9AC7-02229D620301Q35977217-D9BF2E99-3D1C-4C84-A646-0ADE2CDF1F18Q36106061-3C749404-3DF5-4FA5-9733-4EE79E622936Q36312379-A671F281-2F4C-474E-865A-94E8F4B7263FQ36366420-8526F2D8-37CD-4C92-91A6-20B917F4B3C7Q36376333-FEA5D535-B05A-4180-AC1E-E292E8A3449DQ36832141-3B47BF4D-C555-4FCE-AEFE-A68D0E3D5483Q40845817-61BEA3F7-D295-4C6A-8EF9-7A597C3E348EQ40974532-FB6D893E-908E-46ED-8C9B-0A00387DE61FQ41365177-DB68A0A7-9703-41DF-AC4D-18CE2C8EDE17Q41552414-7BD7AD1E-C2EF-479C-B978-C7D21182604BQ47960256-2E21C210-4E48-430F-B17B-32558F91D438Q55354182-B38EF8F8-2AE2-4230-BD08-4DE8EEFD3677
P2860
The multichain interleukin-2 receptor: a target for immunotherapy.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
The multichain interleukin-2 receptor: a target for immunotherapy.
@ast
The multichain interleukin-2 receptor: a target for immunotherapy.
@en
type
label
The multichain interleukin-2 receptor: a target for immunotherapy.
@ast
The multichain interleukin-2 receptor: a target for immunotherapy.
@en
prefLabel
The multichain interleukin-2 receptor: a target for immunotherapy.
@ast
The multichain interleukin-2 receptor: a target for immunotherapy.
@en
P2093
P1476
The multichain interleukin-2 receptor: a target for immunotherapy.
@en
P2093
Junghans RP
Waldmann TA
P304
P356
10.7326/0003-4819-116-2-148
P407
P577
1992-01-01T00:00:00Z